Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Immuno Cure BioTech acquires Shanghai Teresa Healthcare

Integrating Electroporation Technology & DNA Vaccine Platforms

HONG KONG SAR - Media OutReach - 20 September 2022 - Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today the acquisition of 92.6% of Shanghai Teresa Healthcare, the pioneer of electroporation technology and device in China.

The transaction will be settled in cash and shares. Teresa's shareholders will swap for about 1.5% equity in Immuno Cure while the inventor of Teresa's EP technology, Professor XU Yuhong (徐宇虹), maintains her 7.4% direct equity in Teresa.

Teresa EP device delivers brief electrical pulses to promote efficient penetration of DNA vaccine through cell membrane for the enhancement of gene expression and ultimate immune responses. It is the only such device approved by National Medical Products Administration for the administration of DNA vaccine in China. Such EP technology has been an integral part of Immuno Cure's DNA vaccine delivery strategy from research to clinical stage.

Founded in 2004, Shanghai Teresa is an innovative medical device group focusing in electro immunotherapies and rehabilitation therapies. In 2005, Teresa's electroporation technology was developed to enhance the delivery of DNA medicine, based on the intellectual property generated by Shanghai Jiao Tong University under the National 863 Project. Such EP technology has been proven safe and efficacious after deployment of over 10,000 times in collaboration with more than thirty hospitals for the administration of DNA medicine in numerous human trial subjects.

Immuno Cure has two PD-1-Enhanced DNA vaccines currently in phase 1 clinical trial for prevention of COVID-19 and therapeutic cure of HIV/AIDS.

Dr JIN Xia, CEO of Immuno Cure said, "Immuno Cure has partnered with Teresa over the years in developing customised EP delivery strategy for our PD-1-Enhanced DNA vaccines, which has brought about encouraging results in clinical setting recently. I am pleased with this convergence with Teresa, which will no doubt bring our teams even closer together. Teresa will continue to operate independently while leveraging on Immuno Cure's R&D platform for the development of their next generation non-invasive EP technology for intradermal delivery strategy. Immuno Cure is committed to support the continual growth and success of Teresa."

Ms. CHEN Liye, CEO of Teresa said, "Founded on our long term collaboration, Teresa is excited to become a member of Immuno Cure Group. This move will not only provide us with a much closer R&D relationship, which is essential for our technology advancement but also offer us the financial capability to meet future needs. Teresa treasures our collaborations with other players in the field and look forward to continuing our collaborations with new and sustainable EP technology."

Professor CHEN Zhiwei, Director of AIDS Institute at the University of Hong Kong and the Principal Scientific Advisor of Immuno Cure said, "Our research and development work at the AIDS Institute and Immuno Cure has benefitted from Teresa's EP technology and their diligent collaborative effort over the past 12 years. I am pleased to see their relationship developing into an even closer tie. Look forward to the development of the next generation of EP technology for further optimisation of delivery strategy and patient experience."

Dr Percy CHENG, Chairman of Immuno Cure concludes, "This transaction offers Immuno Cure the opportunity to secure Teresa's EP technology for support of not only R&D but also the clinical administration of our PD-1-Enhanced DNA vaccines. We are pleased with Professor XU's decision to remain as our co-investor in Teresa and are optimistic in the future of EP technology in our DNA vaccine development."Hashtag: #ImmunoCureBiotech

The issuer is solely responsible for the content of this announcement.

Immuno Cure BioTech

Immuno Cure BioTech is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of vaccines and immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-Enhanced DNA vaccine and Anti-Δ42PD1 Blocking Antibody technology platforms.

To learn more about Immuno Cure BioTech, please visit

Shanghai Teresa Healthcare

Founded in 2004, Shanghai Teresa is an innovative medical device group based in Shanghai Zhangjiang Hi-Tech Park, focusing in electro immunotherapies and rehabilitation therapies.

To learn more about Shanghai Teresa Healthcare, please visit




News from Asia

XTransfer, VPBank and SmartPay Announce Partnership at Singapore FinTech Festival 2026

Empowering SMEs in Vietnam–China and Vietnam–ASEAN TradeSINGAPORE – Media OutReach Newswire – 19 November 2026 – XTransfer, the world's leading B2B cross-border trade payment platform, VPBank, a...

Columbia Asia Hospital Tebrau and Columbia Asia Hospital Iskandar Puteri jointly achieve Malaysia Book of Records recognition for their Mega Parenthood Workshop 2026

JOHOR BAHRU, MALAYSIA – Media OutReach Newswire – 19 November 2026 – Becoming a parent is one of life's most beautiful journeys, filled with excitement, questions and, at times, uncertainty. Recog...

Lambency Detailing becomes GTECHNIQ Accredited Detailer at both outlets and launches its new e-commerce website

Partnership brings GTECHNIQ’s accredited-only Crystal Serum Ultra to Ubi and Bukit Batok with a 10-year warranty; the new lambencydetailing.com launches the same day with online purchase and bookin...

Uthoppia House Founder Yusup Ngadimin Receives 2026 Spirit of Enterprise Start-up Award

Recognition marks a milestone in the Singapore AI company’s journey to help individuals and employers make more informed career and talent decisionsSINGAPORE– Media OutReach Newswire – 19 November...

UnionPay International Debuts Digital Trade Solution at CIIE 2026, Streamlining Cross-Border B2B Settlement for Global E-Commerce

SHANGHAI, CHINA – Media OutReach Newswire – 19 November 2026 — UnionPay International (UPI), together with Bank of China and Shanghai E&P International, today officially unveiled its Digital T...

DNA Brands Co Marks Fourth Anniversary, Building on Its Growth in Singapore’s Beauty and Wellness Industry

Celebrating four years of progress, the Singapore company looks to elevate its achievements through people, innovation and a shared passion for beauty and wellness as self-care becomes an increasin...

LittleLives, Little Lab and SEGi College Sign MOU to Explore Early Childhood Education Collaboration Across ASEAN

SUBANG JAYA, MALAYSIA - Media OutReach Newswire - 20 November 2026 – LittleLives, Little Lab and SEGi College signed a Memorandum of Understanding (MOU) on 5 November 2026 to explore collaboration...

Bosideng Marks 50 Years with ‘Warmth Code’ Exhibition in Shanghai

SHANGHAI, CHINA – Media OutReach Newswire – 20 November 2026 – Bosideng marked its 50th anniversary with 'Warmth Code: Half a Century of History', a landmark exhibition at Gate M West Bund Dream C...

Sixth Asia International Innovation and Invention Hong Kong Showcases Over 180 Innovations from the Asia-Pacific

Hong Kong Exporters’ Association’s “Hong Kong Innovation and Invention” Program exhibits at Entrepreneur Day for the fourth consecutive yearHONG KONG SAR – Media OutReach Newswire – 20 November 20...

Travel Insurance Was Built for the Few Who Claim. Ancileo’s Felt Coverage™ is for Everyone Else

There are now two kinds of travel insurance: coverage that’s contracted, and coverage that’s felt. Ancileo is the first to introduce the latter.SINGAPORE – Media OutReach Newswire – 20 November 20...

New Research Highlights What Australian Retailers Need to Deliver

New research among Australian SHEIN customers reveals how price comparisons, product quality and customer reviews are shaping purcha...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...